HOME >> BIOLOGY >> NEWS
Although controversial, stem cell therapies exhibit potential in biotechnology markets

SAN ANTONIO June 11, 2002 Stem cells have enormous potential for repairing damage to the body caused by disease, injury, or aging. When introduced into an injured area of a patient, a stem cell could survive and repopulate the region with different types of cells, forming normal tissue.

Stem cells also offer the prospect of treating many inherited diseases caused
by a single, defective gene. Though other
treatments are available, such as gene therapy,
the longevity of benefits from stem cell treatment
provides a tantalizing option for researchers.

Heated controversy has arisen over the ethics of using embryonic stem cells, extracted from either very early embryos or fetuses. The United States has now limited stem cell use to a relatively small number of existing cell lines.

Stem cells are pluripotent, possessing the ability to differentiate into other types of cells. However, other stem cells, which are not derived from embryos and not completely pluripotent, have great potential to differentiate into cells, redeveloping certain tissues or organs. Hematopoietic cells, found in the bone marrow and umbilical cord, for example, can differentiate into all types of blood cells.

In order to make stem cell therapy a reality, it is not only necessary to have suitable stem cells, but also to know how to direct their differentiation and formation of new tissues. Scientists have begun to make new discoveries concerning genes and their protein products that govern various types of cell differentiation, but additional research is imperative.

Stem cell therapies are inherently more complicated than drug treatment, providing a stumbling block for stem cell therapy in the marketplace. However, while stem cell therapy remains costly, it will almost certainly last for several years before the procedure must be repeated. A low annual cost of $2500 per patient for stem cell therapy products at the manufacturers l
'"/>

Contact: Julia Rowell
jrowell@frost.com
210-247-3870
Technical Insights
12-Jun-2002


Page: 1 2

Related biology news :

1. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
2. Serotonin metabolites in mollusks suggest pathways for human therapies
3. Columbia, Stony Brook, Guidant to develop biological pacemaker based on gene & cell therapies
4. Researchers identify two potential protein targets for new drug therapies for pancreatic cancer
5. Insight into transplant rejection might lead to novel prevention therapies
6. Scientists find second way to kill cancer cells: Discovery opens possibilities for new therapies
7. Insights on stroke from the peripheral blood suggest ways to develop markers and therapies
8. Novel approaches to current cellular therapies continue progress toward disease prevention
9. Novel therapies show promise against myeloid leukemia
10. Scientists discover potential approaches to enhance existing cancer therapies
11. Clock cells, tumor suicide, tailored therapies among subjects of AACR-NCI-EORTC Conference

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
Cached News: